Real-World Safety of Aliskiren in Primary Hypertension: A Cross-Database Study

• The report investigates safety signals for aliskiren, used in primary hypertension, by analyzing large-scale post-marketing surveillance data.
• The study draws on two pharmacovigilance databases, aiming to identify rare or under-recognized adverse events and inform clinical practice and regulatory decisions.

FDA Adverse Event Reporting System (FAERS) and the WHO-VigiAccess database.

• Retrospective, quantitative signal-detection analysis of aliskiren-related adverse event reports.
• Data were drawn from the U.S.
• Four signal-detection methods were employed: Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).

• The combined datasets yielded 5,596 (FAERS) and 5,549 (VigiAccess) aliskiren-related reports.
• Across both sources, the median reported duration of adverse events was 62 days, with an interquartile range of 7 to 282 days.

• Adverse event signals spanned 28 System Organ Classes (SOCs).
• Notable signals emerged in investigations, cardiac disorders, renal and urinary disorders, vascular disorders, and disorders of metabolism and nutrition.
• These signals met the criteria for significance according to the four applied algorithms.

• A total of 607 preferred terms (PTs) showed significant disproportionality signals across the four methods.
• Among these: events not widely documented before, including palpitations, myalgia, proteinuria, muscular weakness, pulmonary edema, and pollakiuria, were flagged as potential AEs.

• The analysis corroborates known adverse reactions associated with aliskiren but also points to additional potential risks that warrant attention in pharmacovigilance.
• The findings underscore the value of ongoing safety monitoring in post-marketing contexts to balance therapeutic benefits with emergent safety signals.
• For clinicians, the results suggest a broader consideration of possible adverse events when using aliskiren for primary hypertension, reinforcing careful monitoring and reporting.

• The summary explicitly notes limitations inherent to spontaneous reporting databases (e.g., reporting bias, lack of incidence data, and variable data quality); the source does not quantify causality or incidence rates.
• It is not reported whether certain signals were replicated across databases with consistent directionality or how confounders were addressed.

• The study provides a structured signal framework that may inform heightened vigilance for a broader set of potential AEs in real-world settings.
• Further work is needed to determine the clinical significance, causality, and incidence of the newly implicated terms, and to translate signals into actionable safety guidance.